tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schwartz JJ et al. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. 2007 Transplantation pmid:17893604
Andrades KM et al. Modulation of Candida albicans virulence by antirejection immunosuppressant drugs. 2013 Transplantation pmid:23380869
Tydén G et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. 2007 Transplantation pmid:17496528
Faguer S et al. Rituximab therapy for acute humoral rejection after kidney transplantation. 2007 Transplantation pmid:17496547
Rodrigo E et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. 2016 Transplantation pmid:26703349
Benito N et al. Alternariosis after liver transplantation. 2001 Transplantation pmid:11740399
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
Pescovitz MD et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. 2009 Transplantation pmid:19855247
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Kim CD et al. Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. 2010 Transplantation pmid:20842074
Miroux C et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. 2012 Transplantation pmid:22743548
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Gathogo E et al. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. 2016 Transplantation pmid:26413990
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Demmers MW et al. Limited efficacy of immunosuppressive drugs on CD8+ T cell-mediated and natural killer cell-mediated lysis of human renal tubular epithelial cells. 2014 Transplantation pmid:24704664
Xue F et al. Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. 2010 Transplantation pmid:20010326
Papadopoulos-Köhn A et al. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. 2015 Transplantation pmid:25208324
Manitpisitkul W et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. 2009 Transplantation pmid:19584685
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Winkler ME et al. Successful pregnancy in a patient after liver transplantation maintained on FK 506. 1993 Transplantation pmid:7506460
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Busuttil RW et al. General guidelines for the use of tacrolimus in adult liver transplant patients. 1996 Transplantation pmid:8607197
de Graav GN et al. A Randomized Controlled Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. 2017 Transplantation pmid:28403127
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Watanabe M et al. Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. 2013 Transplantation pmid:23860082
Lenaers JI et al. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. 2006 Transplantation pmid:17102764
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
Atkison PR et al. Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. 1997 Transplantation pmid:9311719
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Yamamoto S et al. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. 2004 Transplantation pmid:15591950
Tan HP et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. 2004 Transplantation pmid:15591960
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Mahé E et al. Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. 2004 Transplantation pmid:14966435
Wallia A et al. Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. 2010 Transplantation pmid:20098286
Araki M et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. 2006 Transplantation pmid:16477217
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Vivarelli M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 2010 Transplantation pmid:20098287
Gallon L et al. ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. 2006 Transplantation pmid:16477235
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Sanchez EQ et al. Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. 2010 Transplantation pmid:20098288
Niioka T et al. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. 2012 Transplantation pmid:23073468
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Swinnen LJ et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. 2008 Transplantation pmid:18645482
Hayashi S et al. Effect of adenovirus-mediated transfer of the CTLA4IG gene in hamster-to-rat xenotransplantation. 2005 Transplantation pmid:16123724
Wannhoff A et al. Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. 2014 Transplantation pmid:25022236
Sureshkumar KK and Chopra B In search of an optimal induction agent in kidney transplantation. 2014 Transplantation pmid:24978038
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Pascual M et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. 1998 Transplantation pmid:9869086
Ciancio G et al. Review of major clinical trials with mycophenolate mofetil in renal transplantation. 2005 Transplantation pmid:16251852
Srinivas TR et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. 2005 Transplantation pmid:16251854
Buell JF et al. Malignancy after transplantation. 2005 Transplantation pmid:16251858
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Strumph P et al. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. 1995 Transplantation pmid:7542815
Zaltzman JS A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. 2010 Transplantation pmid:21166111
Markus PM et al. Effects of in vivo treatment with FK506 on natural killer cells in rats. 1991 Transplantation pmid:1707562
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Fridell JA et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. 2002 Transplantation pmid:12499888
Aw MM et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. 2003 Transplantation pmid:12660504
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Charpentier B et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. 2003 Transplantation pmid:12660513
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Anil Kumar MS et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. 2005 Transplantation pmid:16210969
van Boekel GA et al. Effect of mild diarrhea on tacrolimus exposure. 2012 Transplantation pmid:22955188
Ellis D et al. Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy. 2007 Transplantation pmid:17589338
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Arai K et al. Limb allografts in rats immunosuppressed with FK506. I. Reversal of rejection and indefinite survival. 1989 Transplantation pmid:2479130
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
MacDonald AS Impact of immunosuppressive therapy on hypertension. 2000 Transplantation pmid:11152235
Gillard P et al. Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. 2014 Transplantation pmid:24770614
Brito-Costa A et al. Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. 2016 Transplantation pmid:27136260
Gruessner RW et al. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. 2004 Transplantation pmid:15239611
de Jonge H et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. 2010 Transplantation pmid:20592652
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Bazerbachi F et al. Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. 2013 Transplantation pmid:23183776
Gralla J and Wiseman AC The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. 2010 Transplantation pmid:20595929
Shibasaki S et al. Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. 2013 Transplantation pmid:23269193
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Sher LS et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. 1997 Transplantation pmid:9256184
Tricot L et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. 2005 Transplantation pmid:16371923
Opelz G and Döhler B Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. 2011 Transplantation pmid:21452411
Veenhof H et al. Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. 2017 Transplantation pmid:27906832
Jin L et al. Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. 2018 Transplantation pmid:29319618
MacPhee IA and Holt DW A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. 2008 Transplantation pmid:18212618
Rayar M et al. High Intrapatient Variability of Tacrolimus Exposure in the Early Period After Liver Transplantation Is Associated With Poorer Outcomes. 2018 Transplantation pmid:29315140
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Tourret J et al. Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. 2017 Transplantation pmid:27681266